Targeting the S2 Subsite Enables the Structure-Based Discovery of Novel Highly Selective Factor XIa Inhibitors

Abstract excerpt

FXIa inhibition has been a promising strategy for treating thrombotic diseases. Up to date, many small-molecule FXIa inhibitors have been identified; however, most of them exhibit undesirable selectivity over the homologous plasma kallikrein (PKal). By employing structure-based drug design strategies, we identified many novel selective FXIa inhibitors that have extra interactions with the S2 subsite of FXIa....

Topics

Join the communities discussing this publication.

• Blood Coagulation and Thrombosis Mechanisms
• Coagulation, Bradykinin, Polyphosphates, and Angioedema
• Protease and Inhibitor Mechanisms